Critical Analysis: MeiraGTx (NASDAQ:MGTX) & Big Cypress Acquisition (OTCMKTS:BCYP)

MeiraGTx (NASDAQ:MGTX) and Big Cypress Acquisition (OTCMKTS:BCYP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for MeiraGTx and Big Cypress Acquisition, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0	0	2	0	3.00
Big Cypress Acquisition	0	0	0	0	N/A

MeiraGTx presently has a consensus target price of $22.50, suggesting a potential upside of 429.41%. Given MeiraGTx’s higher possible upside, equities analysts plainly believe MeiraGTx is more favorable than Big Cypress Acquisition.

Insider & Institutional Ownership

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 60.2% of Big Cypress Acquisition shares are owned by institutional investors. 8.4% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares MeiraGTx and Big Cypress Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-1,146.81%	-152.82%	-56.41%
Big Cypress Acquisition	N/A	N/A	N/A

Valuation & Earnings

This table compares MeiraGTx and Big Cypress Acquisition”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$8.12 million	33.65	-$84.03 million	($1.17)	-3.63
Big Cypress Acquisition	N/A	N/A	-$10,000.00	N/A	N/A

Big Cypress Acquisition has lower revenue, but higher earnings than MeiraGTx.

Summary

MeiraGTx beats Big Cypress Acquisition on 5 of the 9 factors compared between the two stocks.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

About Big Cypress Acquisition

Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.